Proton Therapy vs. Carbon-Ion Therapy: Which Is Better as of 2026?

Neither treatment is simply "better" than the other — what matters is which one is right for you. When protecting normal tissue is the top priority, proton therapy is considered; for tumors that don't respond well to conventional radiation, carbon-ion therapy is considered.

Key takeaways

• Proton therapy and carbon-ion (heavy-ion) therapy are both classified as particle therapy, a form of radiation treatment. Both rely on the Bragg peak principle, in which particles stop at a set depth, sparing the normal tissue lying beyond the tumor (National Cancer Center Korea).
• Protons are mainly considered for tumors near structures that are hard to recover if damaged — pediatric cancers, and tumors near the eye, brain, spinal cord, or skull base. Their cancer-killing power is similar to that of conventional X-ray radiation.
• Carbon ions are heavier than protons and cause stronger double-strand breaks in tumor DNA, so this approach is also tried on tumors that responded poorly to conventional radiation.
• In Korea, proton therapy has been introduced and is already in operation, while carbon-ion therapy began its first domestic treatments in 2023.
• Length of stay typically differs: proton therapy generally requires 4–7 weeks including the planning stage (10–35 sessions), while carbon-ion therapy generally requires 3–4 weeks (4–16 sessions).

How do proton and carbon-ion therapy differ in principle?

• Both use the Bragg peak, where particles release their energy and stop at a specific depth, but they differ in particle mass and in how they damage DNA.
• Protons are accelerated hydrogen nuclei. Radiation barely reaches tissue lying behind the tumor. Their biological cancer-killing effect is similar to conventional X-ray radiation, and their main strength lies in sparing surrounding tissue.
• Carbon ions are accelerated carbon nuclei. Being heavier than protons, they cause stronger breaks on both strands of cancer cell DNA. This allows them to act even on the oxygen-poor interior of tumors that do not respond well to conventional radiation.
• Carbon-ion therapy facilities require equipment on the scale of an entire building, so relatively few operating facilities exist worldwide.

When is proton therapy considered, and when is carbon-ion therapy considered?

• The deciding question is whether protecting normal tissue is the priority, or whether radiation resistance is the main problem.
• Proton therapy is considered for pediatric cancers, head and neck cancers, brain tumors, chordomas, and ocular melanoma — cases where the tumor sits right next to the eye, brain, or spinal cord and surrounding tissue absolutely must be protected — as well as for localized tumors such as hepatocellular carcinoma, some lung cancers, and esophageal cancer, where nearby organs need protection.
• Carbon-ion therapy is considered as an alternative for solid tumors with relatively well-defined borders that may respond weakly to conventional radiation — such as prostate cancer, hepatocellular carcinoma, some lung cancers, pancreatic cancer, and bone/soft-tissue sarcoma — or for tumors in locations that are difficult or impossible to operate on, or in patients who cannot tolerate surgery.
• Neither therapy is a standard indication for cancers that have spread to multiple organs, stomach/colorectal cancers that grow widely along the intestinal wall, or blood cancers such as leukemia and lymphoma — surgery or systemic treatment comes first in these cases.
• Recurrence at a site that has already received radiation therapy may also be considered, but records of the previous irradiation site and dose are essential.

How do session count, length of stay, and side effects differ?

• Proton therapy requires 1–2 weeks for simulation imaging and treatment planning, followed by outpatient visits 5 days a week for 10–35 sessions depending on cancer type, for a total stay of 4–7 weeks. Each visit takes around 30 minutes including setup.
• Carbon-ion therapy requires 1–2 weeks for planning, followed by outpatient visits 4–5 days a week for 4–16 sessions depending on cancer type, for a total stay of 3–4 weeks.
• Neither treatment causes pain during irradiation itself, and both are given on an outpatient basis in principle. Common reactions are fatigue and skin changes at the irradiated site. Other side effects depend on the treatment area: pelvic irradiation may cause changes in urination or bowel movements, liver irradiation may cause temporary changes in liver enzyme levels, and lung irradiation may cause coughing or shortness of breath — most of these resolve within a few weeks after treatment.
• Treatment response is not assessed immediately after irradiation but confirmed through imaging over several months. It is common for the tumor to still appear on imaging right after treatment, and this does not mean the treatment failed.

FAQ — Are there cases where neither treatment is possible?

Yes. Cancers that have spread to multiple organs and blood cancers are not standard indications for either proton or carbon-ion therapy; surgery or drug therapy comes first in these cases. Being indication-specific treatments is a shared characteristic of both therapies, and a more expensive treatment is not automatically the right treatment.

FAQ — I previously received radiation therapy in another country. Is treatment still possible?

It depends on the site previously irradiated and the total dose received. If you submit your previous radiation therapy records — including the irradiated site, total dose, number of fractions, and treatment dates — our medical staff will review them at the review stage and provide a written opinion stating whether re-irradiation is possible and whether proton or carbon-ion therapy would be appropriate.

Sources and notes

• This article was written based on notes on proton therapy, carbon-ion therapy, and radiation therapy (National Cancer Center Korea, NCCN Guidelines for Patients, and Medical Korea by the Korea Health Industry Development Institute).
• This content is provided for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment decisions should always be made in consultation with a physician.